GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
713
c/compounding·posted 2 months ago by u/receptor_bias_rick

[Question] how do you actually verify telehealth

Question Long Haul ×9

Genuine question, and the title is the question: how do you actually verify telehealth.

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.

A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.

Would rather be corrected in public than confident in private.

830 up / 117 down88% upvoted30 commentsid kkwenz29 May 2026

30 comments

22 in this archive, depth 5

best — the order this archive was captured in

u/rafael_ostergaard57 points·2 months ago

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

replysharereportpermalink
u/receptor_bias_rickOP25 points·2 months ago

the pharmacy and the prescriber are two separate questions

replysharereportpermalink
u/ireland_drugs_pay20 points·1 months ago

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.

replysharereportpermalink
u/receptor_bias_rickOP14 points·2 months ago

Correcting my own comment: the shortage status changed in the interim, so the arrangement I described no longer applies.

replysharereportpermalink
u/mikkel_correia4 points·2 months ago

Correcting my own comment: the shortage status changed in the interim, so the arrangement I described no longer applies.

Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.

replysharereportpermalink
u/receptor_bias_rickOP67 points·2 months ago

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.

replysharereportpermalink
u/naomi_erdogan17 points·2 months ago

Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.

replysharereportpermalink
u/marit_laurent51 points·2 months ago

That figure is the starting material purity, not the finished preparation potency. Two different tests.

replysharereportpermalink
u/ayesha_radich40 points·2 months ago

Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.

replysharereportpermalink
u/lina_ndiaye25 points·2 months ago

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

replysharereportpermalink
u/rekha_mwangi6 points·2 months ago

a 503B has to register and report, so there is a paper trail to ask for

replysharereportpermalink
u/step_therapy_s20 points·2 months ago

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material.

Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.

replysharereportpermalink
u/hydration_hank9 points·2 months ago

the label on a compounded vial is a legal document, read it

replysharereportpermalink
u/camila_mensa2 points·1 months ago

the label on a compounded vial is a legal document, read it

hydration_hank is right about the concentration trap. It breaks arithmetic that has been reliable for months.

replysharereportpermalink
u/honest_syringe24 points·2 months ago

That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.

replysharereportpermalink
u/receptor_bias_rick7 points·2 months ago

On concentration, which is where I see people actually get hurt.

A compounded vial can be filled at a different concentration from the branded product you were previously using. If you carry over your old arithmetic — same number of units, different mg/mL — you draw a different amount and may not notice for weeks.

Read the label every time you switch. Redo the arithmetic on paper. Write the concentration on the vial. It is the same habit c/reconstitution keeps preaching and this is the case where it actually bites.

replysharereportpermalink
u/ayesha_radich19 points·2 months ago

Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.

replysharereportpermalink
u/chidi_demir-35 points·2 months ago

Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.

replysharereportpermalink
u/marit_laurent12 points·2 months ago

What did the intake actually ask you?

replysharereportpermalink
u/kavya_kravchenko3 points·2 months ago

Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.

replysharereportpermalink
u/formulary_fighterappeals4 points·1 months ago

potency testing on the finished preparation is the thing to ask for

replysharereportpermalink
u/solene_eriksen2 points·1 months ago

ask which facility, then ask for their testing

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/compounding

Compounded GLP-1s as a supply route: the 503A/503B distinction, the shortage-list mechanics that made compounding legal and then didn't, state board rules, telehealth prescriber models, and what a compounding pharmacy will and will not tell you about its API source.

53kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/compounding rules
  1. Regulatory claims need a citation to the actual rule, notice or docket.
  2. No pharmacy referral codes. Naming a pharmacy is fine; recruiting for it is not.
  3. API source questions are on-topic and pharmacies dodging them is newsworthy.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.